Donald Trump & Roche

Donald Trump: Donald Trump announced new tariffs on various imported goods, aiming to boost domestic manufacturing and reduce the budget deficit, despite warnings of increased inflation and harm to consumers.

Roche: Roche, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.

Donald Trump: Donald Trump, as the former U.S. President, was instrumental in the preliminary agreement that reduced punitive tariffs on Swiss goods, leading to the investment pledge.

Roche: Roche is expanding its output in North Carolina as part of the Swiss investment surge.

Donald Trump: President Donald Trump's statements regarding potential attacks on Iran and the possibility of a peace deal influenced market sentiment and oil prices.

Roche: Roche agreed to pay Nurix Therapeutics up to $2.3 billion for rights to an experimental blood-cancer drug.

Donald Trump: As President, Trump's administration has pushed back on mRNA technology, but the trial results may influence policy and public perception.

Roche: Roche is developing a similar personalized mRNA cancer vaccine, and the positive results validate the approach, potentially benefiting its pipeline.

Donald Trump: Donald Trump>>>'s administration's past decision to withdraw from the World Health Organization>>> and cut foreign aid was criticized for weakening surveillance systems.

Roche: Roche is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Roche: Roche's vice chair, André Hoffmann, is a co-chair of the World Economic Forum annual meeting.